PolyPid provides corporate update and reports Q3 2026 results
FROM THE WIRE · GLOBENEWSWIRE.COM
D-PLEX₁₀₀ NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations Ongoing
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralThe D-PLEX100 NDA under FDA priority review with a November 28, 2026 PDUFA date is a relevant catalyst for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The D-PLEX100 NDA is under FDA priority review.
- 02The PDUFA goal date is November 28, 2026.
- 03U.S. commercial launch preparations are ongoing.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets